Madrigal Pharmaceuticals (MDGL) is at a pivotal inflection point, offering a highly asymmetrical risk-reward setup. The company's newly launched drug, REZDIFFRA, is the first FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH), a market that has long been elusive for biotech investors. Despite the stock's volatility, the current setup presents a compelling opportunity for long-term investors.
Key Factors Driving the Opportunity
Strong Early Sales with a Long Runway
Q4 2024 sales came in at $100-$103M, showing an impressive 61% quarter-over-quarter growth.
However, only 4% of the addressable market has been treated, meaning there’s a vast runway for growth.
Medicare coverage starting in 2025 and an anticipated European launch later this year will significantly expand the market potential.
The Market is Underestimating the Path to Blockbuster Status
Analysts project $515M in 2025 sales, but some believe the drug could hit $5-8B in peak annual revenue if adoption accelerates.
If MDGL can maintain its growth trajectory, the company could turn profitable sooner than expected, alleviating some of the typical cash burn concerns that burden biotech stocks.
Competition is Years Behind
Viking Therapeutics (VKTX) is developing a similar THR-β agonist, but it’s still at least two years away from commercialization.
GLP-1 drugs like Novo Nordisk’s (NVO) Semaglutide may play a role, but they are likely to be complementary, not direct competitors. 25% of REZDIFFRA patients are already using GLP-1s, further supporting the idea of combination therapies.
Buyout Speculation vs. Fundamental Growth
MDGL has experienced price swings tied to M&A rumors, but the fundamentals of the business should drive long-term upside, not just a potential buyout.
However, with biotech deals recently trading at 4-5x peak sales, a buyout could value MDGL at a premium to its current market cap.
Short Interest Adds to the Volatility
Short interest in MDGL sits at 22%, reflecting bearish sentiment from some market players.
This high short interest can create significant volatility, but it also presents an opportunity for a short squeeze if the company continues to execute on its growth plan.
Risk vs. Reward: The Asymmetry in MDGL
The Risk: MDGL is not yet profitable and has experienced losses as it scales its commercial efforts. If adoption falters or competition intensifies, its valuation could come under pressure.
The Reward: If REZDIFFRA continues its trajectory, MDGL could reach a valuation in the $10B+ range, with long-term upside well beyond $500 per share as it becomes a dominant player in MASH and expands into new markets.
Unlike many biotech stocks that rely on uncertain trial results, MDGL already has an FDA-approved drug that’s seeing real revenue traction. The next 12-18 months will determine if the company becomes the dominant player in MASH or faces stiffer competition. Either way, the current risk-reward profile seems skewed to the upside, particularly with the high short interest adding a layer of potential for volatility-driven gains.
Disclosure: The content provided in this Substack post is for informational and educational purposes only and should not be construed as investment advice. The author is not a registered financial advisor, and all opinions expressed are solely those of the author. Investing in stocks, options, and biotech companies involves significant risk, including the potential loss of principal. Readers should conduct their own due diligence and consult with a qualified financial professional before making any investment decisions. The author may hold positions in the securities mentioned.